Sustained Retinal Delivery of Baicalin and Ranibizumab Overcomes the Anti-VEGF Monotherapy Dilemma in wAMD.
An intravitreal injectable hydrogel (Rab&BCL-M@G) that co-encapsulates ranibizumab (Rab) and a small-sized baicalin-loaded microemulsion (BCL-M) is developed, enabling controlled and sustained co-delivery of both agents to the retina for over 14 days, proposing a promising synergistic strategy, advancing wAMD therapy t...